triethyl 4-oxocyclohexane-1,1,3-tricarboxylate | 57899-62-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: triethyl 4-oxocyclohexane-1,1,3-tricarboxylate
• 英文别名: triethyl 4-oxocyclohexane-1,1.3-tricarboxylate；2,4,4-tricarbethoxycyclohexanone；4-oxo-cyclohexane-1,1,3-tricarboxylic acid triethyl ester；4-Oxo-cyclohexan-1,1,3-tricarbonsaeure-triaethylester；Ethyl-4,4-dicarboethoxycyclohexanone-2-carboxylate；2,4,4-tricarbethoxy-cyclohexanone
• CAS: 57899-62-4
• 化学式: C₁₅H₂₂O₇
• 分子量: 314.335
• InChiKey: AZZZPEZAKWSDAJ-UHFFFAOYSA-N

物化性质

• 沸点：
  186 °C(Press: 30 Torr)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  96
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  triethyl 4-oxocyclohexane-1,1,3-tricarboxylate 在 对甲苯磺酸一水合物 、 sodium chloride 作用下， 以 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 5.7h， 生成 diethyl 1,4-dioxaspiro[4.5]decane-8,8-dicarboxylate
  参考文献：
  名称：

  氧杂双环辛烷连接的新型细菌拓扑异构酶抑制剂作为广谱抗菌剂。

  摘要：

  细菌耐药性正在侵蚀现有抗生素的临床实用性，因此有必要发现新的药物。II型细菌拓扑异构酶是经过临床验证，高效且经过验证的药物靶标。该靶标易于被具有与喹诺酮抗生素具有替代和不同结合位点的各种抑制剂的抑制作用，从而使得能够开发出对喹诺酮类缺乏交叉耐药性的药物。在此描述的是新型细菌拓扑异构酶抑制剂（NBTI），它是一类新型的回旋酶和topo IV抑制剂，由三个不同的结构部分组成。接头部分的取代导致发现有效的广谱NBTI，其脱靶活性降低（hERG IC50> 18μM），并改善了物理性能。AM8191具有杀菌作用，并选择性抑制DNA合成和金黄色葡萄球菌促旋酶（IC50 = 1.02μM）和topo IV（IC50 = 10.4μM）。在金黄色葡萄球菌鼠感染模型中，AM8191在小于2.5 mg / kg剂量下显示出肠胃外和口服功效（ED50）。与金黄色葡萄球菌DNA旋涡酶结合的AM8191的共晶体结

  DOI：

  10.1021/ml500069w
• 作为产物：
  描述：

  tetraethyl pentane-1,3,3,5-tetracarboxylate 在 sodium ethanolate 作用下， 以 乙醚 为溶剂， 生成 triethyl 4-oxocyclohexane-1,1,3-tricarboxylate
  参考文献：
  名称：

  Oligo(Cyclohexylidene)s and Oligo(Cyclohexyl)s as Bridges for Photoinduced Intramolecular Charge Separation and Recombination

  摘要：

  A series of semirigid donor-bridge-acceptor (D-B-A) molecules was synthesized to study the effect of the position and number of nonconjugated olefinic bonds in the bridge on the photoinduced charge-separation and charge-recombination kinetics. The molecules consist of a phenylpiperidine electron donor, an oligo(cyclohexylidene) or oligo(cyclohexyl) bridge, and a dicyanovinyl acceptor. Partly saturated ter(cyclohexylidene) bridges were used as well. The edge-to-edge donor-acceptor separation of the compounds under study varies between 2.89 and 15.4 Angstrom. The replacement of a C-C single bond by an olefinic bond increases the rate of charge separation with a factor of 3.0 +/- 0.8 per replaced bond. For all D-B-A compounds the extended fully charge-separated state folds to a compact charge-transfer (CCT) conformer. The rate of charge recombination (CR) of the CCT state increases with solvent polarity for those compounds having an olefinic bond located three sigma bonds from the acceptor. Thus, while in cyclohexane the CR rate is equal for all compounds, in benzene the CR rate in compounds with an olefinic bond near the acceptor is 10 times larger than in compounds with a single bond instead. It is believed that a (virtual) charge-transfer state involving the radical cation of the olefinic bond and the radical anion of the acceptor (D-B.+-A(.-)) is responsible for the enhanced CR process.

  DOI：

  10.1021/jp0271716

文献信息

• [EN] HIV INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS D'INTÉGRASE DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012078834A1

  公开（公告）日：2012-06-14

  The disclosure generally relates to the novel compounds of formula (I), including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  该披露通常涉及到式（I）的新化合物，包括它们的盐，这些化合物抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病有用。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。
• Spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and AP-1 inhibitors containing the same
  申请人：Toyama Chemical Co., Ltd.

  公开号：US06384065B1

  公开（公告）日：2002-05-07

  The spiro compounds of the present invention represented by the general formula: wherein A, R2, R3, R4, R5, R6 and n are as defined in the specification, exhibit an AP-1 activity inhibitory action and, based on the AP-1 inhibitory action, suppresses the expression of a wide variety of genes and are useful as an agent for treating and preventing autoimmune diseases with lessoned side reactions.

  本发明的螺环化合物由以下一般式表示：其中A、R2、R3、R4、R5、R6和n如规范中所定义，表现出AP-1活性抑制作用，并基于AP-1抑制作用，抑制各种基因的表达，可用作治疗和预防自身免疫疾病并减少副作用的药剂。
• [EN] BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS BICYCLIQUES PONTÉS POUR LE TRAITEMENT DES INFECTIONS BACTÉRIENNES
  申请人：KYORIN SEIYAKU KK

  公开号：WO2013003383A1

  公开（公告）日：2013-01-03

  Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

  本文披露了新型桥环双环化合物，以及它们的药用盐、水合物和前药。还披露了包含这些化合物的组合物，制备这些化合物的方法以及将这些化合物用作抗菌剂的方法。所披露的化合物、其药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，可用于治疗细菌感染及相关疾病和症状。
• [EN] NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] NOUVEAUX DÉRIVÉS D'ARYLALCÈNE ET UTILISATION DE CEUX-CI EN TANT QUE MODULATEURS SÉLECTIFS DE RÉCEPTEUR D'OESTROGÈNE
  申请人：CENTAURUS BIOPHARMA CO LTD

  公开号：WO2013097773A1

  公开（公告）日：2013-07-04

  The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.

  该发明提供了一种新型的乙烯衍生物，其化学式为I，可用作选择性雌激素受体调节剂（SERMs），并在预防和/或治疗依赖雌激素的疾病或症状方面具有用处。
• Certain cycloalkyl imidazopyrimidines; a new class of GABA brainreceptor
  申请人：Neurogen Corporation

  公开号：US05185446A1

  公开（公告）日：1993-02-09

  This invention encompasses compounds of the formula: ##STR1## and pharmaceutically acceptable non-toxic salts thereof wherein n is 0,1 or 2 and X is --N.dbd.C--R.sub.9 or NR.sub.10 --C.dbd.T where R.sub.1, R.sub.2, R.sub.3, and R.sub.9 and R.sub.10 and X, Y, W and T are variables. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdoes with benzodiazepine type drugs, and enhancement of alertness.

  这项发明涵盖了以下化合物的公式：##STR1##及其药学上可接受的无毒盐，其中n为0、1或2，X为--N.dbd.C--R.sub.9或NR.sub.10--C.dbd.T，其中R.sub.1、R.sub.2、R.sub.3和R.sub.9、R.sub.10以及X、Y、W和T为变量。这些化合物是高度选择性的GABAa脑受体的激动剂、拮抗剂或逆向激动剂，或其前药，可用于焦虑、睡眠和癫痫障碍的诊断和治疗，苯二氮卓类药物过量以及提高警觉性。